Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer.
Three phase I/II trials were performed in patients with metastatic colorectal cancer using immunochemotherapy--a combination of recombinant interferon beta and gamma with low doses of cytostatic drugs. The third regimen, consisting of a cytostatic component containing 5-fluorouracil plus carboplatin plus mitomycin C besides the interferons, produced a high remission rate of 47%: 14/30 patients responded. The tolerability of this protocol was good and it could be administered on an out-patient basis.
Klein
H O
HO
Department of Internal Medicine, University of Cologne, Federal Republic of Germany.
Golbach
G
G
Voigt
P
P
Coerper
C
C
Bernhardt
C
C
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D016899:Interferon-beta / Q000008:administration & dosage* / Q000627:therapeutic use; D007371:Interferon-gamma / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage; D012074:Remission Induction
D011994:Recombinant Proteins; C048341:mafosfamide; D016899:Interferon-beta; D007371:Interferon-gamma; D003520:Cyclophosphamide; D007069:Ifosfamide